Skip to main content
NCBI home page
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 1988 Jul 1;168(1):95–105. doi: 10.1084/jem.168.1.95

Tolerance to tumor necrosis factor in rats and the relationship to endotoxin tolerance and toxicity

PMCID: PMC2188973  PMID: 3294337

Abstract

Treatment of rats with recombinant human TNF initially causes a marked decrease in food intake, a loss of body weight, and a negative nitrogen balance. These alterations normalize with continued twice daily intraperitoneal injections of the same dose. Rats tolerized to TNF in this manner are refractory to a lethal dose of TNF. Also, TNF- pretreated and -tolerized rats have prolonged survival and reversed histopathologic changes after injection of a lethal dose of endotoxin compared with control animals. The TNF-tolerant state is dependent on the dose of TNF used and the length of TNF pretreatment. TNF-induced tolerance is relatively short lived, being present 2-4 d after TNF pretreatment and dissipating by 2 wk. Rats made tolerant to endotoxin are also tolerant to a lethal dose of TNF. A bidirectional crossreacting tolerance exists between TNF and endotoxin. The mechanism of TNF tolerance is unclear, but it does not appear to be due to a humoral immune response or a perturbation of the uptake and clearance of injected TNF.

Full Text

The Full Text of this article is available as a PDF (804.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Asher A., Mulé J. J., Reichert C. M., Shiloni E., Rosenberg S. A. Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J Immunol. 1987 Feb 1;138(3):963–974. [PubMed] [Google Scholar]
  2. Bagby G. J., Corll C. B., Thompson J. J., Wilson L. A. Lipoprotein lipase-suppressing mediator in serum of endotoxin-treated rats. Am J Physiol. 1986 Oct;251(4 Pt 1):E470–E476. doi: 10.1152/ajpendo.1986.251.4.E470. [DOI] [PubMed] [Google Scholar]
  3. Balkwill F., Osborne R., Burke F., Naylor S., Talbot D., Durbin H., Tavernier J., Fiers W. Evidence for tumour necrosis factor/cachectin production in cancer. Lancet. 1987 Nov 28;2(8570):1229–1232. doi: 10.1016/s0140-6736(87)91850-2. [DOI] [PubMed] [Google Scholar]
  4. Beeson P. B., Technical Assistance of Elizabeth Roberts TOLERANCE TO BACTERIAL PYROGENS : I. FACTORS INFLUENCING ITS DEVELOPMENT. J Exp Med. 1947 Jun 30;86(1):29–38. doi: 10.1084/jem.86.1.29. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Beutler B., Cerami A. Cachectin and tumour necrosis factor as two sides of the same biological coin. Nature. 1986 Apr 17;320(6063):584–588. doi: 10.1038/320584a0. [DOI] [PubMed] [Google Scholar]
  6. Beutler B., Cerami A. Cachectin: more than a tumor necrosis factor. N Engl J Med. 1987 Feb 12;316(7):379–385. doi: 10.1056/NEJM198702123160705. [DOI] [PubMed] [Google Scholar]
  7. Beutler B., Milsark I. W., Cerami A. C. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science. 1985 Aug 30;229(4716):869–871. doi: 10.1126/science.3895437. [DOI] [PubMed] [Google Scholar]
  8. Cerami A., Beutler B. The role of cachectin/TNF in endotoxic shock and cachexia. Immunol Today. 1988 Jan;9(1):28–31. doi: 10.1016/0167-5699(88)91353-9. [DOI] [PubMed] [Google Scholar]
  9. Chapman P. B., Lester T. J., Casper E. S., Gabrilove J. L., Wong G. Y., Kempin S. J., Gold P. J., Welt S., Warren R. S., Starnes H. F. Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer. J Clin Oncol. 1987 Dec;5(12):1942–1951. doi: 10.1200/JCO.1987.5.12.1942. [DOI] [PubMed] [Google Scholar]
  10. Decker T., Lohmann-Matthes M. L., Gifford G. E. Cell-associated tumor necrosis factor (TNF) as a killing mechanism of activated cytotoxic macrophages. J Immunol. 1987 Feb 1;138(3):957–962. [PubMed] [Google Scholar]
  11. Flick D. A., Gifford G. E. Comparison of in vitro cell cytotoxic assays for tumor necrosis factor. J Immunol Methods. 1984 Mar 30;68(1-2):167–175. doi: 10.1016/0022-1759(84)90147-9. [DOI] [PubMed] [Google Scholar]
  12. Greisman S. E., Young E. J., Woodward W. E. Mechanisms of endotoxin tolerance. IV. Specificity of the pyrogenic refractory state during continuous intravenous infusions of endotoxin. J Exp Med. 1966 Nov 1;124(5):983–1000. doi: 10.1084/jem.124.5.983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Imamura K., Spriggs D., Kufe D. Expression of tumor necrosis factor receptors on human monocytes and internalization of receptor bound ligand. J Immunol. 1987 Nov 1;139(9):2989–2992. [PubMed] [Google Scholar]
  14. Lang C. H., Spitzer J. A. Glucose kinetics and development of endotoxin tolerance during long-term continuous endotoxin infusion. Metabolism. 1987 May;36(5):469–474. doi: 10.1016/0026-0495(87)90045-x. [DOI] [PubMed] [Google Scholar]
  15. Oettgen H. F., Old L. J. Tumor necrosis factor. Important Adv Oncol. 1987:105–130. [PubMed] [Google Scholar]
  16. Peacock J. L., Gorschboth C. M., Norton J. A. Impact of insulin on doxorubicin-induced rat host toxicity and tumor regression. Cancer Res. 1987 Aug 15;47(16):4318–4322. [PubMed] [Google Scholar]
  17. Rogers T. S., Halushka P. V., Wise W. C., Cook J. A. Differential alteration of lipoxygenase and cyclooxygenase metabolism by rat peritoneal macrophages induced by endotoxin tolerance. Prostaglandins. 1986 Apr;31(4):639–650. doi: 10.1016/0090-6980(86)90171-1. [DOI] [PubMed] [Google Scholar]
  18. Smith R. A., Kirstein M., Fiers W., Baglioni C. Species specificity of human and murine tumor necrosis factor. A comparative study of tumor necrosis factor receptors. J Biol Chem. 1986 Nov 15;261(32):14871–14874. [PubMed] [Google Scholar]
  19. Tracey K. J., Beutler B., Lowry S. F., Merryweather J., Wolpe S., Milsark I. W., Hariri R. J., Fahey T. J., 3rd, Zentella A., Albert J. D. Shock and tissue injury induced by recombinant human cachectin. Science. 1986 Oct 24;234(4775):470–474. doi: 10.1126/science.3764421. [DOI] [PubMed] [Google Scholar]
  20. Tracey K. J., Fong Y., Hesse D. G., Manogue K. R., Lee A. T., Kuo G. C., Lowry S. F., Cerami A. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature. 1987 Dec 17;330(6149):662–664. doi: 10.1038/330662a0. [DOI] [PubMed] [Google Scholar]
  21. Tracey K. J., Lowry S. F., Fahey T. J., 3rd, Albert J. D., Fong Y., Hesse D., Beutler B., Manogue K. R., Calvano S., Wei H. Cachectin/tumor necrosis factor induces lethal shock and stress hormone responses in the dog. Surg Gynecol Obstet. 1987 May;164(5):415–422. [PubMed] [Google Scholar]
  22. Unglaub R., Maxeiner B., Thoma B., Pfizenmaier K., Scheurich P. Downregulation of tumor necrosis factor (TNF) sensitivity via modulation of TNF binding capacity by protein kinase C activators. J Exp Med. 1987 Dec 1;166(6):1788–1797. doi: 10.1084/jem.166.6.1788. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES